ADAMAS PHARMACEUTICALS, INC. (NASDAQ:ADMS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On April 17, 2017, Adamas Pharmaceuticals, Inc. entered into an offer letter with Richard A. King to which Mr. King will become Adamas’ Chief Operating Officer, effective April 28, 2017.

Mr. King, age 52, has held executive leadership roles at numerous companies in the life sciences industry throughout his career. Most recently, from May 2016 to April 2017, Mr. King was Chief Operating Officer at The Scripps Research Institute, where he was responsible for strategic planning, business development, finance, human resources, facilities, information technology and research services. He previously served as President and Chief Executive Officer of AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company developing new pain medications, from May 2010 to March 2015, where he was responsible for overseeing all aspects of AcelRx’s business. Prior to AcelRx, he was President, Chief Operating Officer and General Manager of the biotechnology company Tercica, Inc. (later sold to the Ipsen Group), where he was instrumental in the commercial launch of Dysport^®>(abobotulinumtoxinA) and Increlex™ (rhlGF-1). He also previously served as Executive Vice President of commercial operations at Kos Pharmaceuticals, Inc., where he oversaw the growth of Niaspan^®>(niacin extended-release) and the launch of Advicor^® (niacin extended-release/lovastatin). He was Senior Vice President of commercial operations at Solvay and Vice President of commercial operations at Unimed, where he launched AndroGel^®>(testosterone gel). Earlier in his career, he held positions of increasing responsibility at SmithKline Beecham and Lederle Laboratories. Mr. King received a B.Sc. in chemical engineering from the University of Surrey in the U.K. and an M.B.A. from the Manchester Business School in the U.K.

Mr. King’s offer letter with Adamas provides that Mr. King will receive, as compensation: an annual base salary of $470,000; a bonus to be determined in accordance with Adamas’ bonus plan, with a target bonus of 40% of his annual base salary; a sign-on advance of $204,250; a stock option to purchase 168,750 shares of Adamas common stock with an exercise price per share equal to the fair market value per share of Adamas common stock on the date of grant, which vests with respect to 25% of the shares after one year and then in equal monthly installments thereafter over the next three years; and a restricted stock unit to acquire 28,125 shares of Adamas common stock, which vests with respect to 25% of the shares each year over four years.